Transgene SA (EPA:TNG)
France · Delayed Price · Currency is EUR | Market Cap | 199.39M +27.6% |
| Revenue (ttm) | 5.62M -25.8% |
| Net Income | -33.90M |
| EPS | -0.16 |
| Shares Out | 273.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,132 |
| Open | 0.7540 |
| Previous Close | 0.7550 |
| Day's Range | 0.7240 - 0.7540 |
| 52-Week Range | 0.6700 - 1.3650 |
| Beta | 0.79 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
About Transgene
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050... [Read more]
Financial Performance
In 2025, Transgene's revenue was 7.21 million, an increase of 13.49% compared to the previous year's 6.35 million. Losses were -37.52 million, 10.5% more than in 2024.
Financial StatementsNews
Transgene Earnings release: Q3 2026
Transgene released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Transgene Earnings release: H1 2026
Transgene released its H1 2026 earnings on September 24, 2026, summarizing the period's financial results.
Transgene Quarterly report: H1 2026
Transgene has published its H1 2026 quarterly earnings report on September 24, 2026.
Transgene Slides: H1 2026
Transgene has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 24, 2026.
Transgene Slides: Investor presentation
Transgene has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Transgene Transcript: Status update
Significant advances were presented in individualized neoantigen vaccines, with TG4050 progressing in head and neck cancer and TG4070 launching in non-small cell lung cancer. Manufacturing is transitioning to a scalable cell line process, and the SNIPER platform is validated for future indications. Expansion into Monkeypox/Smallpox vaccines leverages these innovations.
Transgene Press release: Status update
Transgene issued a press release on June 29, 2026, disclosing material business information to investors.
Transgene Slides: Status update
Transgene has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Transgene Slides: Investor presentation
Transgene has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Transgene Earnings release: Q1 2026
Transgene released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Transgene Earnings Call Transcript: H2 2025
Strong clinical progress in 2025 with TG4050 showing 100% disease-free survival in phase I, robust fundraising securing operations through early 2028, and preparations for new trials and manufacturing scale-up. Key data readouts and industry partnerships are anticipated in the coming years.
Transgene Annual report: H2 2025
Transgene has published its H2 2025 annual report on March 24, 2026.
Transgene Earnings release: H2 2025
Transgene released its H2 2025 earnings on March 24, 2026, summarizing the period's financial results.
Transgene Slides: H2 2025
Transgene has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
Transgene Transcript: Status Update
TG4050 demonstrated 100% disease-free survival at 24 months in phase I for operable head and neck cancer, with robust, durable T cell responses and strong translational support for its mechanism. Phase II and new combination trials are progressing, with key data expected from 2026 onward.
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
STRASBOURG, France--(BUSINESS WIRE)---- $TNG--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced tha...
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022
Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and Bi...
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
STRASBOURG, France--(BUSINESS WIRE)-- #HBV--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces...
R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
STRASBOURG, France--(BUSINESS WIRE)-- #HBV--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, wil...
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
STRASBOURG, France--(BUSINESS WIRE)---- $TNG--New positive TG6002 Phase I data confirm the mechanism of action of this oncolytic virus when administered intravenously.